ÂÜÀòÂÒÂ×

Teghpal Singh is a seasoned professional in the biopharmaceutical industry with extensive experience in early commercial strategy, product planning, and competitive intelligence. Currently serving as Senior Director of Early Commercial Strategy at SpringWorks Therapeutics, Teghpal previously held leadership roles at Takeda Oncology, Sanofi Genzyme, and Blueprint Medicines. Teghpal's expertise encompasses immuno-oncology, multiple myeloma, and acute myeloid leukemia, alongside a strong background in strategic market assessments and competitive insights. Educational credentials include a Ph.D. in Neuroscience from the University of Maryland School of Medicine and a Postdoctoral Research Associate position at Brown University, supplemented by training in immunology from Harvard Medical School.